Superworth

AN2 Therapeutics EPS ANTX

Diluted earnings per share by quarter and over the last twelve months, from 2021.

Last 12 months, to Jun 30, 2026
−$1.07
Latest quarter, Q2 FY26
−$0.18
Fiscal year 2025
−$1.16

AN2 Therapeutics' earnings per share was −$1.07 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.18.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.16n/a
FY2024−$1.72n/a
FY2023−$2.82n/a
FY2022−$4.71n/a
FY2021−$10.61n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.18n/a−$1.07
Q1 FY26−$0.29n/a−$1.10
Q4 FY25−$0.29n/a−$1.16
Q3 FY25−$0.31n/a−$1.12
Q2 FY25−$0.21n/a−$1.24
Q1 FY25−$0.35n/a−$1.51
Q4 FY24−$0.25n/a−$1.72
Q3 FY24−$0.43n/a−$2.04
Q2 FY24−$0.48n/a−$2.26
Q1 FY24−$0.56n/a−$2.59
Q4 FY23−$0.57n/a−$2.82
Q3 FY23−$0.65n/a−$2.86

Against its peers

Companies in Drug Manufacturers - General nearest AN2 Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
ANTXAN2 Therapeutics−$1.07
NATRNatures Sunshine Products$1.01+36% a year
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
ATNMActinium Pharmaceuticals$0.36
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
Peer median$0.65

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on AN2 Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.